ReviewCurrent oncology (Toronto, Ont.)2019
Role of real-world evidence in informing cancer care: lessons from colorectal cancer.
Review in Current oncology (Toronto, Ont.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- First-line therapies for unresectable hepatocellular carcinoma: a network meta-analysis of immune checkpoint inhibitors and transarterial therapies based on 35 randomized trials.Frontiers in oncology · 2026Pooled it
- Pooled it
- Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Pooled it
- Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?Journal of comparative effectiveness research · 2026Review
- Review
- Finding the right tool for the specific task: navigating RWE tools and checklists.Future oncology (London, England) · 2025Review
- Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis.ESMO real world data and digital oncology · 2024Article
- Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence.Future oncology (London, England) · 2024Article
- Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada.PharmacoEconomics - open · 2023Article
- Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2023Article
- Promise of Real-World Evidence for Patient Centricity in Gulf Cooperation Council Countries: Call to Action.Drugs - real world outcomes · 2023Article
- Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective.The oncologist · 2022Article
- Observational
- Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.Clinical pharmacology and therapeutics · 2022Article
- Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.Targeted oncology · 2021Article
- Harnessing real-world evidence to reduce the burden of noncommunicable disease: health information technology and innovation to generate insights.Health services & outcomes research methodology · 2021Article
- Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries.Frontiers in oncology · 2021Article
- Eligibility of real-world patients with metastatic breast cancer for clinical trials.Breast (Edinburgh, Scotland) · 2020Article
- Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer.World journal of gastrointestinal oncology · 2020Review
- Are we finally moving toward personalized therapy in colorectal cancer?Current oncology (Toronto, Ont.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term "real-world evidence" (rwe) describes the analysis of data that are collected beyond the context of clinical trials. The use and application of rwe have become increasingly common and relevant, especially in oncology, because there is growing recognition that randomized controlled trials (rcts) might not be sufficiently representative of the entire patient population that is affected by cancer, and that specific clinical research questions might be best addressed by real-world data. In this brief review, our main aim is to highlight the role of rwe in informing cancer care, particularly focusing on specific examples from colorectal cancer. Our hope is to illustrate the ways in which rwe can complement rcts in improving the understanding of cancer management and how rwe can facilitate cancer treatment decisions for real-world patients encountered in routine clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.